For Immediate Release
Chicago, IL – March 23, 2021 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amazon.com, Inc. (
AMZN Quick Quote AMZN - Free Report) , Visa Inc. ( V Quick Quote V - Free Report) , Medtronic plc ( MDT Quick Quote MDT - Free Report) , American Express Company ( AXP Quick Quote AXP - Free Report) and Mondelez International, Inc. ( MDLZ Quick Quote MDLZ - Free Report) . Here are highlights from Monday’s Analyst Blog: Top Stock Reports for Amazon, Visa and Medtronic
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Visa, and Medtronic. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see
all of today’s research reports here >>> Amazon shares have underperformed the broader market over the past year (+63.9% vs. +76.6%), though the stock has lagged lately as interest rates have gone up. The Zacks analyst believes that Amazon is gaining on solid Prime momentum owing to ultrafast delivery services and expanding content portfolio.
Further, a coronavirus-led spike in online orders continues to be a major tailwind. Also, solid growth in its online stores sales remains a positive. Moreover, the surge in online grocery shopping is another positive. Additionally, the strong adoption rate of AWS is aiding the company’s cloud dominance.
Further, improving Alexa skills and expanding smart home products portfolio are positives. However, accelerating coronavirus related expenses remain risks for the company’s margin expansion in the near term. Also, rising cloud competition poses risk.
) read the full research report on Amazon here >>> Visa shares have gained +7.2% over the last six months against the Zacks Financial Transaction Services industry’s gain of +2.5%. The Zacks analyst believes that numerous acquisitions and alliances paved the way for long-term growth and consistently drove revenues for the company.
Shift in payments to the digital modes is a boon too. The acquisition of Visa Europe is a strategic fit as well. The coronavirus vaccine development and the gradual revival of consumer confidence will drive spending, expanding the company's business volumes in turn.
Ramped-up client initiatives will dent the top line. Also, a sluggish cross-border business due to coronavirus looms on.
) read the full research report on Visa here >>>
Medtronic have gained +2.4% in the past three months against the Zacks Medical Products industry’s gain of +3.7%. The Zacks analyst believes that all major business groups have been contributing to consistent revenue growth at CER, which highlights sustainability across groups and regions.
Meanwhile, Respiratory, Gastrointestinal, & Renal as well as Specialty Therapies, Neuromodulation and Diabetes Group registered year-over-year growth on an organic basis in the third-quarter fiscal 2021.
However, performance of the rest of the business segments deteriorated. The company’s performance was primarily impacted by deferred procedures due to the pandemic during December and January.
) read the full research report on Medtronic here >>>
Other noteworthy reports we are featuring today include American Express and Mondelez International.
Zacks Top 10 Stocks for 2021
In addition to the stocks discussed above, would you like to know about our 10 best buy-and-hold tickers for the entirety of 2021?
Last year's 2020
Zacks Top 10 Stocks portfolio returned gains as high as +386.8%. Now a brand-new portfolio has been handpicked from over 4,000 companies covered by the Zacks Rank. Don’t miss your chance to get in on these long-term buys. Access Zacks Top 10 Stocks for 2021 today >>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss
. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.